FOSTER CITY (dpa-AFX) - Gilead Sciences, Inc. (GILD) Wednesday announced
positive results from two-year interim analysis of the ongoing ASSURE study
evaluating the company's investigational drug seladelpar for the treatment of
primary biliary cholangitis (PBC), a rare, chronic inflammatory liver disease.

The two-year interim analysis included patients who participated in any prior
clinical studies of seladelpar (legacy studies) and participants from the
pivotal Phase 3 RESPONSE study. The positive results from the two-year interim
analysis were highly consistent with one-year interim analysis.

Results from the study showed rapid and sustained improvements in markers of
cholestasis, including high rates of normalization of liver biomarkers and a
clinically meaningful reduction in pruritus in patients treated with seladelpar.

These data were shared in a presentation during the European Association for the
Study of the Liver (EASL) Congress 2024 in Milan, Italy.



Copyright(c) 2024 RTTNews.com. All Rights Reserved

Copyright RTT News/dpa-AFX